Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 4
2017 4
2018 1
2019 1
2020 1
2021 1
2022 3
2023 3
2024 4
2025 4
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean sacubitril[All Fields] AND VALSARTAN[All Fields] (2,807 results)?
Effects of BNP and Sacubitrilat/Valsartan on Atrial Functional Reserve and Arrhythmogenesis in Human Myocardium.
Primessnig U, Deißler PM, Wakula P, Tran KL, Hohendanner F, von Lewinski D, Blaschke F, Knosalla C, Falk V, Pieske B, Grubitzsch H, Heinzel FR. Primessnig U, et al. Front Cardiovasc Med. 2022 Jul 5;9:859014. doi: 10.3389/fcvm.2022.859014. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 35865376 Free PMC article.
BACKGROUND: Although the angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril/valsartan started a new era in heart failure (HF) treatment, less is known about the tissue-level effects of the drug on the atrial myocardial functional reserve and arrhythmogenesis. ...I …
BACKGROUND: Although the angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril/valsartan started a new era in heart failure (HF …
Serum concentrations of valsartan and sacubitrilat, the active metabolite of sacubitril, in patients with heart failure with reduced ejection fraction: results of a pilot cross-sectional study.
Lazarova M, Urinovska R, Kacirova I, Grundmann M, Dodulik J, Vaclavik J. Lazarova M, et al. Expert Rev Clin Pharmacol. 2025 Jun;18(6):397-406. doi: 10.1080/17512433.2025.2519644. Epub 2025 Jun 24. Expert Rev Clin Pharmacol. 2025. PMID: 40501207
BACKGROUND: Sacubitril/valsartan is used to treat heart failure. It consists of sacubitril (its active metabolite, sacubitrilat, acts as a neprilysin inhibitor) and valsartan (an angiotensin II type 1 receptor blocker). ...RESULTS: Serum concentrations of …
BACKGROUND: Sacubitril/valsartan is used to treat heart failure. It consists of sacubitril (its active metabolite, sacubitrilat …
Development and validation of a sensitive and simple LC-MS/MS method for simultaneous quantitation of valsartan, sacubitril and sacubitrilat in pediatric population.
Yang Q, Cao P, Lv Y, Peng H, Zhai X. Yang Q, et al. J Pharm Biomed Anal. 2024 Jan 20;238:115829. doi: 10.1016/j.jpba.2023.115829. Epub 2023 Oct 30. J Pharm Biomed Anal. 2024. PMID: 37948774
Trough concentration of the three substances to be measured were: valsartan (11.3-938.0 ng/mL), sacubitril (0.5-395.5 ng/mL) and sacubitrilat (522.1-4890.0 ng/mL). Overall, this is the first study to simultaneously determined the plasma valsartan, sacubitril …
Trough concentration of the three substances to be measured were: valsartan (11.3-938.0 ng/mL), sacubitril (0.5-395.5 ng/mL) and s …
Clinical Pharmacokinetics of Sacubitril/Valsartan (LCZ696): A Novel Angiotensin Receptor-Neprilysin Inhibitor.
Ayalasomayajula S, Langenickel T, Pal P, Boggarapu S, Sunkara G. Ayalasomayajula S, et al. Clin Pharmacokinet. 2017 Dec;56(12):1461-1478. doi: 10.1007/s40262-017-0543-3. Clin Pharmacokinet. 2017. PMID: 28417439 Review.
Absorption of sacubitril/valsartan and conversion of sacubitril (prodrug) to sacubitrilat (neprilysin inhibitor) was rapid with maximum plasma concentrations of sacubitril, sacubitrilat, and valsartan (angiotensin receptor blocker) reaching within 0.5, …
Absorption of sacubitril/valsartan and conversion of sacubitril (prodrug) to sacubitrilat (neprilysin inhibitor) was rapid wit …
Pharmacokinetics and pharmacodynamics of sacubitril/valsartan in peritoneal dialysis patients.
He Y, Jin Y, Xue H, Liu R, Zhang M, Liao R, Chen M, Zhou X, He X, Qin M, Li K, Zou H, Gan Y, Wang Z, Zheng L, Zhong H, Fu P. He Y, et al. Nephrol Dial Transplant. 2023 Jul 31;38(8):1880-1889. doi: 10.1093/ndt/gfad038. Nephrol Dial Transplant. 2023. PMID: 36787894 Free article.
BACKGROUND: There is little information on the pharmacokinetics and pharmacodynamics of sacubitril/valsartan (SV) in patients undergoing peritoneal dialysis (PD) complicated with hypertension or heart failure (HF). ...METHODS: This was an open-label and cross-sectional stu …
BACKGROUND: There is little information on the pharmacokinetics and pharmacodynamics of sacubitril/valsartan (SV) in patients undergo …
Pharmacokinetics and safety of sacubitril/valsartan (LCZ696) in patients with mild and moderate hepatic impairment .
Kulmatycki KM, Langenickel T, Ng WH, Pal P, Zhou W, Lin TH, Rajman I, Chandra P, Sunkara G. Kulmatycki KM, et al. Int J Clin Pharmacol Ther. 2017 Sep;55(9):728-739. doi: 10.5414/CP202988. Int J Clin Pharmacol Ther. 2017. PMID: 28737127
Blood samples were collected at pre-determined time points to assess pharmacokinetics of sacubitril, sacubitrilat, and valsartan. Subjects with severe hepatic impairment were excluded as valsartan exposure is expected to be substantially increased in these pa …
Blood samples were collected at pre-determined time points to assess pharmacokinetics of sacubitril, sacubitrilat, and valsartan …
Neprilysin 2 catalyses the degradation of natriuretic peptides despite sacubitrilat Inhibition.
Selezneva EM, Feygina EE, Ageeva LV, Rozov FN, Kopylova IV, Altshuler EP, Semenov AG. Selezneva EM, et al. Sci Rep. 2025 Jul 28;15(1):27401. doi: 10.1038/s41598-025-10166-z. Sci Rep. 2025. PMID: 40721616 Free PMC article.
This study aimed to investigate NEP2 expression in the cardiovascular system, its ability to cleave natriuretic peptides, and its inhibition by sacubitrilat. NEP and NEP2 expression profiles were assessed using reverse transcription PCR. ...Our results show that sacubit …
This study aimed to investigate NEP2 expression in the cardiovascular system, its ability to cleave natriuretic peptides, and its inhibition …
Erratum to: Clinical Pharmacokinetics of Sacubitril/Valsartan (LCZ696): A Novel Angiotensin Receptor-Neprilysin Inhibitor.
Ayalasomayajula S, Langenickel T, Pal P, Boggarapu S, Sunkara G. Ayalasomayajula S, et al. Clin Pharmacokinet. 2018 Jan;57(1):105-123. doi: 10.1007/s40262-017-0558-9. Clin Pharmacokinet. 2018. PMID: 28527109
Absorption of sacubitril/valsartan and conversion of sacubitril (prodrug) to sacubitrilat (neprilysin inhibitor) was rapid with maximum plasma concentrations of sacubitril, sacubitrilat, and valsartan (angiotensin receptor blocker) reaching within 0.5, …
Absorption of sacubitril/valsartan and conversion of sacubitril (prodrug) to sacubitrilat (neprilysin inhibitor) was rapid wit …
Transforming pediatric heart failure: Efficacy of low-dose sacubitril/valsartan.
Zha H, Zhai X, Wang L, Yang Q, Guo Q, Chen Y, Liu J, Peng H. Zha H, et al. Curr Probl Cardiol. 2025 Jan;50(1):102926. doi: 10.1016/j.cpcardiol.2024.102926. Epub 2024 Nov 6. Curr Probl Cardiol. 2025. PMID: 39510399 Free article. Review.
Clinical efficacy and quantity-effect relationship were evaluated using echocardiography, NT-proBNP, and the concentration of valsartan, sacubitril, sacubitrilat. RESULTS: A total of 23 pediatric patients with dilated cardiomyopathy and advanced heart failure were e …
Clinical efficacy and quantity-effect relationship were evaluated using echocardiography, NT-proBNP, and the concentration of valsartan …
Assessing clinical and biomarker characteristics to optimize the benefits of sacubitril/valsartan in heart failure.
Litwin SE, East CA. Litwin SE, et al. Front Cardiovasc Med. 2022 Dec 22;9:1058998. doi: 10.3389/fcvm.2022.1058998. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 36620638 Free PMC article. Review.
Of the various medical therapies for heart failure (HF), sacubitril/valsartan is a first-in-class angiotensin receptor-neprilysin inhibitor that combines sacubitril, a pro-drug that is further metabolized to the neprilysin inhibitor sacubitrilat, and the angiotensin …
Of the various medical therapies for heart failure (HF), sacubitril/valsartan is a first-in-class angiotensin receptor-neprilysin inh …
23 results